Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib

Michael C. Lynch, Renee Straub, David Adams

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors. Commonly administered for the treatment of metastatic or unresectable hepatocellular carcinoma and advanced renal cell carcinoma, sorafenib has demonstrated remarkable survival benefits for those where curative surgery is not an option. Although generally having a mild side effect profile, sorafenib has been linked to a variety of dermatologic disorders, including most commonly acneiform rash, hand-foot-skin reactions, facial erythema, splinter subungual hemorrhages, alopecia or pruritus. The authors describe a case of sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient with hepatocellular carcinoma. This case adds to the growing literature suggesting a strong correlation between sorafenib and non-melanoma skin cancers including keratoacanthoma and squamous cell carcinoma. Routine dermatologic monitoring of these patients to ensure early detection is highly recommended.

Original languageEnglish (US)
Pages (from-to)308-310
Number of pages3
JournalJournal of Drugs in Dermatology
Volume10
Issue number3
StatePublished - Mar 2011

Fingerprint

Keratoacanthoma
Squamous Cell Carcinoma
Hepatocellular Carcinoma
Alopecia
Physiologic Monitoring
Skin Neoplasms
Erythema
Pruritus
Exanthema
Renal Cell Carcinoma
Foot
Hand
sorafenib
Hemorrhage
Skin
Survival
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Dermatology

Cite this

@article{3c055c81f729474e9851153b11fd88ef,
title = "Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib",
abstract = "Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors. Commonly administered for the treatment of metastatic or unresectable hepatocellular carcinoma and advanced renal cell carcinoma, sorafenib has demonstrated remarkable survival benefits for those where curative surgery is not an option. Although generally having a mild side effect profile, sorafenib has been linked to a variety of dermatologic disorders, including most commonly acneiform rash, hand-foot-skin reactions, facial erythema, splinter subungual hemorrhages, alopecia or pruritus. The authors describe a case of sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient with hepatocellular carcinoma. This case adds to the growing literature suggesting a strong correlation between sorafenib and non-melanoma skin cancers including keratoacanthoma and squamous cell carcinoma. Routine dermatologic monitoring of these patients to ensure early detection is highly recommended.",
author = "Lynch, {Michael C.} and Renee Straub and David Adams",
year = "2011",
month = "3",
language = "English (US)",
volume = "10",
pages = "308--310",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "3",

}

Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. / Lynch, Michael C.; Straub, Renee; Adams, David.

In: Journal of Drugs in Dermatology, Vol. 10, No. 3, 03.2011, p. 308-310.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib

AU - Lynch, Michael C.

AU - Straub, Renee

AU - Adams, David

PY - 2011/3

Y1 - 2011/3

N2 - Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors. Commonly administered for the treatment of metastatic or unresectable hepatocellular carcinoma and advanced renal cell carcinoma, sorafenib has demonstrated remarkable survival benefits for those where curative surgery is not an option. Although generally having a mild side effect profile, sorafenib has been linked to a variety of dermatologic disorders, including most commonly acneiform rash, hand-foot-skin reactions, facial erythema, splinter subungual hemorrhages, alopecia or pruritus. The authors describe a case of sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient with hepatocellular carcinoma. This case adds to the growing literature suggesting a strong correlation between sorafenib and non-melanoma skin cancers including keratoacanthoma and squamous cell carcinoma. Routine dermatologic monitoring of these patients to ensure early detection is highly recommended.

AB - Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors. Commonly administered for the treatment of metastatic or unresectable hepatocellular carcinoma and advanced renal cell carcinoma, sorafenib has demonstrated remarkable survival benefits for those where curative surgery is not an option. Although generally having a mild side effect profile, sorafenib has been linked to a variety of dermatologic disorders, including most commonly acneiform rash, hand-foot-skin reactions, facial erythema, splinter subungual hemorrhages, alopecia or pruritus. The authors describe a case of sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient with hepatocellular carcinoma. This case adds to the growing literature suggesting a strong correlation between sorafenib and non-melanoma skin cancers including keratoacanthoma and squamous cell carcinoma. Routine dermatologic monitoring of these patients to ensure early detection is highly recommended.

UR - http://www.scopus.com/inward/record.url?scp=80053010052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053010052&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 308

EP - 310

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 3

ER -